TargetMol

Icrocaptide

Product Code:
 
TAR-T27581
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27581-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Icrocaptide is used potentially for the treatment of acute myocardial infarction.
CAS:
169543-49-1
Formula:
C21H40N8O5
Molecular Weight:
484.602
Purity:
0.98
SMILES:
CCN([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CN

References

1. Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction).. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J. 2004 Mar;25(5):392-400. PubMed PMID: 15033251. 2. Syeda B, Kiss K, Modarressy K, Sch?nau K, Schukro C, Derntl M, Laggner A, Sochor H, Glogar D. Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: a randomised, placebo-controlled pilot trial. Drugs R D. 2004;5(3):141-51. PubMed PMID: 15139775. 3. Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, Maruyama S, Bertuglia S, Mascagni P, Goligorsky MS. Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia. Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F713-21. doi: 10.1152/ajprenal.00541.2011. PubMed PMID: 22160777; PubMed Central PMCID: PMC3311315. 4. Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D, Cremonesi P, Bhattacharya J, Mascagni P. ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation. Mol Med. 2007 Nov-Dec;13(11-12):615-24. PubMed PMID: 17948065; PubMed Central PMCID: PMC2034195.